GLP-1 receptor agonists are increasingly recognized as a transformative tool in weight management, offering significant benefits for individuals confronting obesity and associated health conditions. These medications operate by suppressing appetite and enhancing satiety, presenting a potent strategy in addressing a widespread health crisis, with wide-ranging implications for personal well-being and public healthcare systems globally.

The journey to a healthy weight can be challenging even for elite athletes. Tennis icon Serena Williams, a holder of 23 Grand Slam singles titles and four Olympic gold medals, openly shared her personal struggles with weight management following the births of her daughters, Olympia in 2017 and Adira in 2023. Despite an intensely disciplined regimen of healthy eating and rigorous professional training—even walking 20,000 to 30,000 steps daily—she found herself unable to lose weight, a frustration she experienced while aiming for peak performance. This additional weight led to significant strain on her joints, a critical concern for any professional tennis player. Recognizing the need for a different approach, Williams explored GLP-1 medications, initially facing hesitation due to the pervasive stigma that these drugs represent a “shortcut” or “cop out.” She firmly rejects this perception, emphasizing, “It’s not a shortcut. It’s not a copout. This is just another tool to support my health journey.”

Serena Williams commenced her GLP-1 regimen approximately a year ago, after concluding breastfeeding Adira. Following an initial pause attributed to nervousness and unresolved questions, she recommenced treatment in January, this time partnering with telehealth provider Ro. She highlighted the ease of experience with Ro, appreciating the accessible support and clear answers from doctors, particularly beneficial given her demanding travel schedule. Now, serving as a celebrity patient ambassador for Ro, Williams is committed to dismantling the stigmas surrounding GLP-1 usage. Seven months into her treatment, she reports benefits extending beyond just weight loss, including noticeably reduced joint strain, enhanced training capacity, and improved health markers, such as better blood sugar levels. She asserts that being on a GLP-1 does not detract from her identity as a professional athlete; rather, it allows her to enjoy sports more and pursue a healthy life by utilizing available medical tools.

The broader landscape of obesity underscores the critical need for effective interventions. In the UK, approximately two out of three adults are classified as obese or overweight, contributing to a substantial 39 percent increase in type 2 diabetes among individuals under 40 and being linked to at least 13 types of cancer. Existing injectable GLP-1 medications, such as Ozempic (semaglutide), Wegovy (semaglutide), and Mounjaro (tirzepatide), have demonstrated considerable efficacy in weight loss. Mounjaro, often referred to as the ‘king kong’ of weight-loss jabs, has shown up to 20-22 percent weight reduction, while Wegovy typically achieves around 15 percent over 72 weeks. These